© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Valeant Acquisition of Salix Pharmaceuticals
Posted 27th February 2015

Valeant Acquisition of Salix Pharmaceuticals

NULL

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Valeant Acquisition of Salix Pharmaceuticals
Image

Valeant Acquisition of Salix Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Ltd. announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies. 

Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of innovative, new assets. 

“Salix’s market-leading gastrointestinal franchise is an ideal strategic fit for Valeant’s diversified portfolio of specialty products,” said J. Michael Pearson, Valeant’s chairman and chief executive officer. “The growing GI market has attractive fundamentals, and Salix has a portfolio of terrific products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products. With strong brand recognition among specialist GI prescribers, a highly rated specialty sales force, and a significant product and commercial presence across the undertreated and underserved gastrointestinal market, this acquisition offers a compelling opportunity for Valeant to create a strong platform for growth and business development.” 

Thomas W. D’Alonzo, Chairman of the Board and Acting Chief Executive Officer of Salix, stated, “We are pleased to have reached an agreement with Valeant, which is a logical partner and importantly, creates immediate value for our shareholders. Combining Salix’s leading market position in gastroenterology with Valeant’s scale and resources will create a stronger and more diverse business committed to providing better health solutions to health care providers and their patients. We are proud of the accomplishments of our Salix team. Together, we have built our company into the leading gastrointestinal specialty pharmaceutical company, providing solutions for patients and healthcare providers. We look forward to working with the Valeant team to ensure a smooth transition.”

To find out more information about either company, please visit www.valeant.com or www.salix.com.

Categories: M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
Nordic Region Rivals US and Europe for Process Excellence Adoption
Innovation
17/02/2015Nordic Region Rivals US and Europe for Process Excellence Adoption

Nokia Labs Head of Operations Jarkko Pellikka, Ph.D says the Nordic region boasts some of the finest examples of process and operational excellence in the world today.

Read Full PostRead - Eye Icon
Taking a Bite Out of Apple
Innovation
24/06/2015Taking a Bite Out of Apple

Taylor Swift trumps technology giant, Apple, as they back down over royalties row.

Read Full PostRead - Eye Icon
Essential Tips on Getting a Title Loan
News
06/03/2024Essential Tips on Getting a Title Loan

Are you ready to deal with an emergency if one comes up? You know something is bound to go wrong at some point, whether it’s a broken water pipe, car repair bill, or unforeseen medical expense. You don’t have the cash to cover the costs in an accou

Read Full PostRead - Eye Icon
AI Ad Specs
Strategy
19/05/2016AI Ad Specs

AI Ad Specs

Read Full PostRead - Eye Icon
Tech-led M&A: How to Attract a Buyer
Leadership
05/06/2019Tech-led M&A: How to Attract a Buyer

The tech sector is one of the most targeted for M&A activity, attracting a wide variety of cross-industry buyers.

Read Full PostRead - Eye Icon
10 Benefits of Studying Public Health
News
10/05/202410 Benefits of Studying Public Health

Image Source Public health plays a pivotal role in shaping the well-being of local communities as well as global populations. Its core aim is to promote community health, prevent diseases, and extend life expectancy through organized efforts and informed choic

Read Full PostRead - Eye Icon
First Steps to Take when Doing Company Acquisition
M&A
17/10/2022First Steps to Take when Doing Company Acquisition

Many people want to have a business they can call their own. However, building one from scratch is not easy. Because of this, many entrepreneurs are choosing to buy an existing business. But buying an existing business is not as easy as buying a used car. You

Read Full PostRead - Eye Icon
Is This Just Fantasy?
Innovation
08/10/2021Is This Just Fantasy?

The world of technology has been revolutionized in the last few years by the rise of VR, AR and 3D simulators. Allowing people access to virtual plains where concepts can be thoroughly visualized and explored, these developments can be seen having an effect on

Read Full PostRead - Eye Icon
Support for US Small Businesses
Leadership
13/11/2015Support for US Small Businesses

In run up to Small Business Saturday Alerus offers support.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow